» Articles » PMID: 21771106

Onychomycosis in Patients with Psoriasis--a Multicentre Study

Overview
Journal Mycoses
Specialty Microbiology
Date 2011 Jul 21
PMID 21771106
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

1-3% of human population is affected by psoriasis. Nail disorders are reported in 10-80% of patients with psoriasis. Nail deformations vary according to their degree of severity but are mainly represented by pitting, Beau's lines, hyperkeratosis, onycholysis, leuconychia or oil drops. Onychomycosis is a fungal infection of the nails, caused by dermatophytes, yeast and moulds. In this study, 228 patients with psoriasis aged between 18 and 72 were examined (48 - from Plovdiv, Bulgaria; 145 - from Pleven, Bulgaria and 35 - from Thessaloniki, Greece); 145 of them were male and 83 of them were female. The examination of the nail material was performed via direct microscopy with 20% KOH and nail samples plated out on Sabouraud agar methodology. The severity of the nail disorders was determined according to the Nail Psoriasis Severity Index (NAPSI). Positive mycological cultures were obtained from 62% of the patients with psoriasis (52%- Plovdiv, Bulgaria; 70%- Pleven, Bulgaria and 43%- Thessaloniki, Greece). In 67% of the cases, the infection was caused by dermatophytes, in 24% by yeast, in 6% by moulds and in 3% by a combination of causes. All patients with psoriasis were identified with high levels of NAPSI, whereas the ones with isolated Candida had even higher levels. Seventeen percentage of the patients have been treated with methotrexate, 6% have been diagnosed with diabetes and 22% have been reported with onychomycosis and tinea pedis within the family. An increased prevalence of onychomycosis among the patients with psoriasis was found. Dystrophic nails in psoriasis patients are more predisposed to fungal infections. The mycological examination of all psoriasis patients with nail deformations is considered obligatory because of the great number of psoriasis patients diagnosed with onychomycosis.

Citing Articles

Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.

Campione E, Artosi F, Shumak R, Giunta A, Argenziano G, Assorgi C Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459016 PMC: 11510175. DOI: 10.3390/ph17101378.


Prevalence of onychomycosis among psoriasis patients: a clinico-mycological and dermoscopic comparative cross sectional study.

Abdo H, Hassab-El-Naby H, Bashtar M, Hasan M, Elsaie M Sci Rep. 2024; 14(1):21743.

PMID: 39289407 PMC: 11408611. DOI: 10.1038/s41598-024-71321-6.


Efficacy of Bovine Nail Membranes as In Vitro Model for Onychomycosis Infected by Species.

Temporiti M, Guerini M, Baiguera R, Buratti S, Desiderio A, Goppa L J Fungi (Basel). 2022; 8(11).

PMID: 36354900 PMC: 9695884. DOI: 10.3390/jof8111133.


Fungal Infections and Nail Psoriasis: An Update.

Kyriakou A, Zagalioti S, Trakatelli M, Fotiadou C, Apalla Z, Lazaridou E J Fungi (Basel). 2022; 8(2).

PMID: 35205908 PMC: 8878282. DOI: 10.3390/jof8020154.


Overall Prevalence and Prevalence Compared among Psoriasis Treatments of Onychomycosis in Patients with Nail Psoriasis and Fungal Involvement.

Chularojanamontri L, Pattanaprichakul P, Leeyaphan C, Suphatsathienkul P, Wongdama S, Bunyaratavej S Biomed Res Int. 2021; 2021:9113418.

PMID: 34938812 PMC: 8687829. DOI: 10.1155/2021/9113418.